SS3L1 Diabetic Eye Disease
Date: 18/06/2019
Venue: ACO, 374 Cardigan St, Carlton, VIC, 3165
Provider: Australian College of Optometry
Contact: Liz Salvatore, [E] cpd@aco.org.au, [P] 03 9349 7477
Learning Objectives
- Explain the factors that should be considered when deciding to initiate treatment in a patient who has been recently diagnosed with diabetic retinopathy (DR)
- Discuss the rationale for the selection of a particular pharmacologic agent when managing a case of proliferative diabetic retinopathy
- Outline the alternatives for DR patients who do not respond adequately to anti-VEGF drugs
- Discuss the current research and future development of more potent pharmacologic agents for the management of DR
Max points awarded: 3.00
Session Information
| Name |
|---|
| SS2L1 Diabetic Eye Disease |
| Activity Type |
| Face to Face with Assessment |
| Therapeutic? |
| No |
| Manufacturer/Supplier? |
| No |
| Points for attending & Passing Assessment |
| 3.00 |
| Name | Activity Type | Therapeutic? | Manufacturer/ Supplier? | Points for attending & Passing Assessment |
|---|---|---|---|---|
| SS2L1 Diabetic Eye Disease | Face to Face with Assessment | No | No | 3.00 |